Moore Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Moore Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-25,000	Closed	-$444K	–	343
2018 Q3	$444K	Buy	+25,000	New	+$429K	0.01%	253
2018 Q2	–	Sell	-50,000	Closed	-$455K	–	354
2018 Q1	$455K	Buy	+50,000	New	+$276K	0.01%	220

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Moore Capital Management's ECYT Position: Q4 2018 in Review

Moore Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 25,000 shares — an estimated $444K sold.

Moore Capital Management first reported a position in ECYT in Q1 2018 and held it in 2 quarters. The position peaked at $455K in Q1 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Moore Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Moore Capital Management sold 25,000 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $444K.
Moore Capital Management first reported a position in Endocyte, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
Moore Capital Management's Endocyte, Inc. Common Stock position peaked at $455K in Q1 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Moore Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.